Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be performed in place of or in combination with other cancer treatments to provide truly comprehensive care. The advantage of these methods is that I.O. has much less effect on the body compared to conventional procedures.
An estimated by IQ4I Research, the interventional oncology global market is expected to grow a high single digit CAGR from 2019 to 2026 to reach $2,119.4 million by 2026. Some of the factors driving the market are increasing prevalence of cancer cases, growing adoption of minimally invasive procedures, increasing geriatric population, technological advancements in the field of interventional oncology, and expansion in the emerging markets.
The interventional oncology market by product is segmented as ablation and embolization. The embolization segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The ablation segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.
Ablation global market by product type, it is segmented into radiofrequency ablation, microwave ablation, cryoablation and others (irreversible electroporation and MRI-guided laser ablation). Among ablation, microwave ablation holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The other segment is the fastest-growing segment with a high double digit CAGR from 2019 to 2026. Embolization global market by product type, it is segmented into Radio-embolization and non-radioembolization. Among embolization, non-radioembolization holds the highest revenue in 2019 and it is expected to grow at a mid single digit CAGR from 2019 to 2026. The radio-embolization segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026. The embolization global market by procedure, it is segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), transcranial chemo-embolization (TACE), drug-eluting beads transcranial chemo-embolization (DEB-TACE) and transcranial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.
Interventional Oncology (I.O.) global market by application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, uterine fibroid and others. Among interventional oncology applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The brain & spine cancer segment is the fastest-growing segment with a low double digit CAGR from 2019 to 2026.
Ablation global market by application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among ablation applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The brain & spine cancer segment is the fastest-growing segment with a low double digit CAGR from 2019 to 2026. Embolization global market by application is segmented into liver cancer, lung cancer, prostate cancer, uterine fibroid and other. Among embolization applications, the liver cancer segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The uterine fibroid segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.
Interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), academics & research institutes. Among end-users, the hospital segment holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026. The ambulatory surgical center segment is the fastest-growing segment with a high single digit CAGR from 2019 to 2026.
Interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, Japan, Australia and Rest of APAC) and Rest of the world (Brazil, Rest of LATAM and Middle East & Others). North America holds the highest revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026 due to adoption of the technological advancements, increasing incidences of cancer, increased training institutes for interventional oncology, increasing demand for minimally invasive surgeries, favorable reimbursement, product launches, skilled personnel, and strong product pipeline. The Asia-Pacific region is the fastest-growing region with a low double digit CAGR from 2019 to 2026 due to increasing geriatric population, increased healthcare facilities, increasing incidence of cancer, increasing awareness about interventional oncology and low-cost for the surgery are driving the market.
The interventional oncology global market is a consolidated market with top 5 players occupying major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (Australia), Boston Scientific Corporation (U.S.), Guerbet (France), Merit Medical System (U.S.), Varian Medical System, Inc. (U.S.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
鈥� North America
o U.S.
o Rest of North America
鈥� Europe
o Germany
o France
o Italy
o Rest of Europe
鈥� Asia-Pacific
o Japan
o China
o Australia
o Rest of APAC
鈥� Rest of the World (RoW)
o Brazil
o Rest of LATAM
o Middle East and Others
1 EXECUTIVE SUMMARY 21
2 INTRODUCTION 27
2.1 KEY TAKEAWAYS 27
2.2 SCOPE OF THE REPORT 28
2.3 REPORT DESCRIPTION 28
2.4 MARKETS COVERED 31
2.5 STAKEHOLDERS 33
2.6 RESEARCH METHODOLOGY 33
2.6.1 MARKET SIZE ESTIMATION 34
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 37
2.6.3 SECONDARY SOURCES 38
2.6.4 PRIMARY SOURCES 39
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 39
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 40
2.6.7 ASSUMPTIONS 40
3 MARKET ANALYSIS 42
3.1 INTRODUCTION 42
3.2 MARKET SEGMENTATION 44
3.3 FACTORS INFLUENCING MARKET 46
3.3.1 DRIVERS AND OPPORTUNITIES 47
3.3.1.1 Increasing prevalence of cancer cases 47
3.3.1.2 Growing adoption of minimally invasive procedures 47
3.3.1.3 Increasing geriatric population 48
3.3.1.4 Technological advancements in the field of interventional oncology 49
3.3.1.5 Expansion in the emerging markets 49
3.3.2 RESTRAINTS AND THREATS 50
3.3.2.1 Side effects and risks associated with the use 50
3.3.2.2 Lack of awareness and understanding about interventional oncology importance 51
3.3.2.3 Lack of trained professionals 51
3.3.2.4 Availability of alternative treatments 52
3.3.2.5 Stringent regulatory guidelines 52
3.4 REGULATORY AFFAIRS 54
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 54
3.4.1.1 ISO 9001: 2015 quality management system 54
3.4.1.2 ISO 13485 MEDICAL DEVICES 55
3.4.1.3 ISO 10993 biological evaluation of medical devices 55
3.4.1.4 ISO 14971 risk management of medical devices 56
3.4.1.5 ISO 12807:2018 safe transport of radioactive materials-leakage testing on packages 56
3.4.1.6 IEC 60601-1 medical electrical equipment standard 56
3.4.1.7 IEC 60601-1-2 electromagnetic compatibility (EMC) for medical devices 56
3.4.2 U.S. 57
3.4.3 CANADA 58
3.4.4 EUROPE 59
3.4.5 JAPAN 59
3.4.6 CHINA 60
3.4.7 INDIA 61
3.5 CLINICAL TRIALS DATA 62
3.6 PORTER鈥橲 FIVE FORCE ANALYSIS 64
3.6.1 THREAT OF NEW ENTRANTS 65
3.6.2 THREAT OF SUBSTITUTES 65
3.6.3 BARGAINING POWER OF SUPPLIERS 66
3.6.4 BARGAINING POWER OF BUYERS 66
3.6.5 COMPETITIVE RIVALRY 67
3.7 SUPPLY CHAIN ANALYSIS 68
3.8 REIMBURSEMENT SCENARIO 71
3.9 REGULATORY APPROVED INTERVENTIONAL ONCOLOGY PRODUCTS BY COMPANY 72
3.10 FUNDING SCENARIO 75
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 77
3.11.1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS 77
3.11.2 ABLATION GLOBAL MARKET SHARE ANALYSIS 80
3.11.3 EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS 82
3.12 INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BY REGION 84
3.12.1 ABLATION DEVICES NUMBER OF UNITS BY REGION 84
3.12.2 RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS BY REGION 86
3.12.3 MICROWAVE ABLATION DEVICES NUMBER OF UNITS BY REGION 88
3.12.4 CRYOABLATION DEVICES NUMBER OF UNITS BY REGION 90
3.13 INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME BY PRODUCT TYPE 92
3.14 MARKET PENETRATION OF INTERVENTIONAL ONCOLOGY BY APPLICATION 95
3.15 INTERVENTIONAL ONCOLOGY COMPANY COMPARISON TABLE BY REVENUE, PRODUCT AND APPLICATION 97
4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY PRODUCT 99
4.1 INTRODUCTION 99
4.2 ABLATION 102
4.2.1 RADIOFREQUENCY ABLATION 106
4.2.2 MICROWAVE ABLATION 109
4.2.3 CRYOABLATION ABLATION 112
4.2.4 OTHER ABLATION 115
4.3 EMBOLIZATION 117
4.3.1 EMBOLIZATION BY PRODUCT TYPE 119
4.3.1.1 Radio-embolization 122
4.3.1.2 Non-radioembolization 124
4.3.2 EMBOLIZATION BY PROCEDURE 127
4.3.2.1 Transarterial radio-embolization (TARE)/selective internal radiation therapy (SIRT) 130
4.3.2.2 Transarterial chemo-embolization (TACE) 132
4.3.2.3 Drug-eluting beads transarterial chemo-embolization (DEB-TACE) 135
4.3.2.4 Bland embolization/ transarterial embolization (TAE) 137
5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY APPLICATION 139
5.1 INTRODUCTION 139
5.1.1 LIVER CANCER 147
5.1.2 KIDNEY CANCER 152
5.1.3 LUNG CANCER 155
5.1.4 BRAIN AND SPINE CANCER 160
5.1.5 PROSTATE CANCER 163
5.1.6 UTERINE FIBROIDS 167
5.1.7 OTHER APPLICATIONS 169
6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BY END-USERS 173
6.1 INTRODUCTION 173
6.1.1 HOSPITALS 176
6.1.2 AMBULATORY SURGICAL CENTERS (ASC鈥橲) 178
6.1.3 ACADEMICS AND RESEARCH INSTITUTES 180
7 REGIONAL ANALYSIS 182
7.1 INTRODUCTION 182
7.2 NORTH AMERICA 187
7.2.1 U.S. 203
7.2.2 REST OF NORTH AMERICA 209
7.3 EUROPE 215
7.3.1 GERMANY 231
7.3.2 FRANCE 237
7.3.3 ITALY 243
7.3.4 REST OF EUROPE 248
7.4 APAC 254
7.4.1 CHINA 270
7.4.2 JAPAN 276
7.4.3 AUSTRALIA 282
7.4.4 REST OF APAC 288
7.5 ROW 294
7.5.1 BRAZIL 310
7.5.2 REST OF LATAM 316
7.5.3 MIDDLE EAST & OTHERS 322
8 COMPETITIVE LANDSCAPE 328
8.1 INTRODUCTION 328
8.2 PRODUCT APPROVAL 329
8.3 ACQUISITION AND PARTNERSHIP 331
8.4 NEW PRODUCT LAUNCH 333
8.5 OTHERS 334
9 MAJOR COMPANIES 338
9.1 ANGIODYNAMICS INC. 338
9.1.1 OVERVIEW 338
9.1.2 FINANCIALS 339
9.1.3 PRODUCT PORTFOLIO 342
9.1.4 KEY DEVELOPMENTS 342
9.1.5 BUSINESS STRATEGY 343
9.1.6 SWOT ANALYSIS 344
9.2 BOSTON SCIENTIFIC CORPORATION 345
9.2.1 OVERVIEW 345
9.2.2 FINANCIALS 346
9.2.3 PRODUCT PORTFOLIO 349
9.2.4 KEY DEVELOPMENTS 349
9.2.5 BUSINESS STRATEGY 350
9.2.6 SWOT ANALYSIS 351
9.3 GUERBET 352
9.3.1 OVERVIEW 352
9.3.2 FINANCIALS 353
9.3.3 PRODUCT PORTFOLIO 356
9.3.4 KEY DEVELOPMENTS 356
9.3.5 BUSINESS STRATEGY 357
9.3.6 SWOT ANALYSIS 358
9.4 JOHNSON & JOHNSON 359
9.4.1 OVERVIEW 359
9.4.2 FINANCIALS 360
9.4.3 PRODUCT PORTFOLIO 363
9.4.4 KEY DEVELOPMENTS 363
9.4.5 BUSINESS STRATEGY 364
9.4.6 SWOT ANALYSIS 365
9.5 MEDTRONIC PLC 366
9.5.1 OVERVIEW 366
9.5.2 FINANCIALS 367
9.5.3 PRODUCT PORTFOLIO 371
9.5.4 KEY DEVELOPMENTS 372
9.5.5 BUSINESS STRATEGY 372
9.5.6 SWOT ANALYSIS 373
9.6 MERIT MEDICAL SYSTEMS, INC. 374
9.6.1 OVERVIEW 374
9.6.2 FINANCIALS 375
9.6.3 PRODUCT PORTFOLIO 379
9.6.4 KEY DEVELOPMENTS 379
9.6.5 BUSINESS STRATEGY 380
9.6.6 SWOT ANALYSIS 381
9.7 MONTERIS MEDICAL 382
9.7.1 OVERVIEW 382
9.7.2 FINANCIALS 382
9.7.3 PRODUCT PORTFOLIO 382
9.7.4 KEY DEVELOPMENTS 383
9.7.5 BUSINESS STRATEGY 384
9.7.6 SWOT ANALYSIS 385
9.8 SIRTEX MEDICAL LIMITED 386
9.8.1 OVERVIEW 386
9.8.2 FINANCIALS 386
9.8.3 PRODUCT PORTFOLIO 386
9.8.4 KEY DEVELOPMENTS 387
9.8.5 BUSINESS STRATEGY 388
9.8.6 SWOT ANALYSIS 389
9.9 TERUMO CORPORATION 390
9.9.1 OVERVIEW 390
9.9.2 FINANCIALS 391
9.9.3 PRODUCT PORTFOLIO 394
9.9.4 KEY DEVELOPMENTS 394
9.9.5 BUSINESS STRATEGY 395
9.9.6 SWOT ANALYSIS 396
9.10 VARIAN MEDICAL SYSTEM INC. 397
9.10.1 OVERVIEW 397
9.10.2 FINANCIALS 398
9.10.3 PRODUCT PORTFOLIO 401
9.10.4 KEY DEVELOPMENTS 401
9.10.5 BUSINESS STRATEGY 402
9.10.6 SWOT ANALYSIS 403
ANGIODYNAMICS, INC.
BOSTON SCIENTIFIC CORPORATION
GUERBET
JOHNSON & JOHNSON
MEDTRONIC PLC
MERIT MEDICAL SYSTEM, INC.
MONTERIS MEDICAL
SIRTEX MEDICAL
TERUMO CORPORATION
VARIAN MEDICAL SYSTEM INC.
LIST OF COMPANIES MENTIONED IN THE REPORT
ABK BIOMEDICAL INC.
ANGIODYNAMICS, INC.
BOSTON SCIENTIFIC CORPORATION
CLINICAL LASERTHERMIA SYSTEMS
DELCATH SYSTEMS, INC
ERBE ELKTROMEDIZIN GMBH
GUERBET
ICECURE MEDICAL
IMBIOTECHNOLOGIES
JOHNSON & JOHNSON
MEDTRONIC PLC
MEDWAVES MEDICAL
MERIT MEDICAL SYSTEM
MISONIX
MONTERIS MEDICAL INC
PROFOUND MEDICAL CORP.
ROYAL PHILLIPS
SANARUS MEDICAL
SIRTEX MEDICAL LIMITED
SONACARE MEDICAL LLC
TERUMO CORPORATION
TROD MEDICAL
VARIAN MEDICAL SYSTEM
听
听
*If Applicable.
